Cure & Advancements/November 7, 2025/2 min read

A £50 Million Push Toward Type 1 Diabetes Cures

The Type 1 Diabetes Grand Challenge aims to accelerate research into restoring insulin production and stopping immune system damage. Because type 1 affects everyone differently, researchers are exploring multiple pathways rather than seeking a single cure for all.

News report — unverified, pending corroboration

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

cure researchbeta cellsadvancements

Key takeaways

Type 1 diabetes damage involves two problems: lost insulin-producing beta cells and immune system attacks. Any cure must address both.
Islet cell transplantation exists today but isn't a cure—transplanted cells are eventually attacked and don't survive long-term.
The new £50 million Type 1 Diabetes Grand Challenge focuses on three high-potential research areas to speed progress toward treatments.
Researchers expect multiple solutions because type 1 diabetes varies widely between individuals based on genetics, environment, and immune factors.

Understanding the Challenge

Type 1 diabetes occurs when the immune system mistakenly attacks and destroys insulin-producing beta cells in the pancreas. To cure the condition, researchers must solve two interconnected problems: restore the pancreas's ability to produce insulin and prevent the immune system from attacking those cells again.

Unlike some conditions, type 1 diabetes doesn't affect everyone in the same way. Genetics, environmental factors, and individual immune differences shape how the disease develops and progresses. This means there is unlikely to be a single cure that works equally well for everyone.

Where We Stand Today

Islet cell transplantation is one treatment available now for some people with severe low blood sugar episodes and loss of warning symptoms. The procedure involves transplanting insulin-producing cells from a donor pancreas.

For some patients, transplantation has reduced or temporarily eliminated the need for insulin therapy. However, it is not a cure. The transplanted donor cells cannot survive long-term because the immune system continues to attack them, much as it attacks a person's own beta cells.

The Grand Challenge Ahead

To accelerate progress, diabetes.org.uk has launched the Type 1 Diabetes Grand Challenge in partnership with the Steve Morgan Foundation and Breakthrough T1D. This £50 million research initiative, made possible by a major gift from the Steven Morgan Foundation, aims to speed development of new treatments and cures.

The challenge focuses on three key research areas with the highest potential to transform care. By concentrating resources and expertise on these priorities, researchers hope to move promising approaches from the laboratory toward patients faster than traditional funding pathways allow.

Evidence label

Origin: diabetes.org.uk (News report). Evidence: News report — unverified, pending corroboration. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.